In the interest of patients and their safety, development of drugs and new therapeutic are the results of long and complicated processes. Next to intensive research, each approach has to undergo several testing phases before it is ready for the market. This generally takes several years.

With our N2B-patch project we are still in the research phase and aim to achieve a proof-of-concept and preclinical validation by the year 2020. Once validated, the approach shall be tested first in the clinic and then on MS patients. After a successful clinical validation and admission, production and market launch can start.

We are convinced that good research results need to include the patient’s perspective and respond to their needs. That is why the voice of MS patients’ represented by the European MS Platform is included from a very early stage on in this N2B-patch project.

Please feel free to get in touch with us! Our team includes the largest association of MS patients in Europe (EMSP). EMSP is the umbrella organisation for 40 MS societies from 35 European countries, representing their interests at the European level.

 

FAQ

This section covers the most frequently asked questions (FAQ’s) regarding the N2B-Patch project as well as provide more information for patients. Are you still not finding the answer you were looking for? Please do not hesitate to contact us.

 

What is the N2B-Patch project?

The N2B-Patch is a project funded by the European Union, which brings together universities, research institutes, SMEs, industry and patients organisations to explore the possibility to have treatments (in MS) that bypass the Blood Brain Barrier.

A full list of all the organisations involved can be found here.

 

Why would you want to bypass the blood brain barrier?

Currently, there is no efficient method to permanently bypass the blood-brain barrier, it is for this reason that this project is so innovative and important.

Bypassing the blood brain barrier could lead to a more effective way of treating MS – and potentially also be a less invasive treatment for patients. Developing a ‘nose to brain’ delivery system, thus bypassing the blood-brain barrier, could avoid the need for injections and oral medicine to treat MS.

 

What are you trying to deliver via this project?

The N2B-Patch aims to deliver three concrete outputs:

  • The first is the drug particle, the treatment for MS
  • The second is the gel, which will serve as a less invasive drug-carrier
  • The third is the device which will apply the drug and gel

The combination of these three outputs will hopefully result in a treatment bypassing the blood brain barrier, thus enabling a more efficient treatment for MS.

 

When will these outputs be of use for patients?

The project itself will run until 2020, however the outputs will not be available for patients in the coming years. The end-results of this project will need to be tested further and only after this is done will they be suited for the market. At this moment we do not yet have a defined timeline.

 

Would this technology be applicable for other diseases than MS?

Although this project focusses on MS, we do envision that this technology will support the treatment of other demyelinating disorders and other central nervous system indications, e.g. stroke, neurodegenerative diseases or tumours.

 

My question is not answered, who do I contact if I have other questions?

For more questions you can always contact the European Multiple Sclerosis Platform (EMSP) at http://www.emsp.org/contact/.